The estimated Net Worth of Eamonn P Hobbs is at least 1.91 百万$ dollars as of 10 September 2014. Mr. Hobbs owns over 9,000 units of Orasure Technologies stock worth over 1,625,396$ and over the last 20 years he sold OSUR stock worth over 98,465$. In addition, he makes 183,305$ as Independent Director at Orasure Technologies.
Eamonn has made over 4 trades of the Orasure Technologies stock since 2009, according to the Form 4 filled with the SEC. Most recently he bought 9,000 units of OSUR stock worth 19,800$ on 10 September 2014.
The largest trade he's ever made was buying 100,000 units of Orasure Technologies stock on 18 November 2009 worth over 360,000$. On average, Eamonn trades about 2,022 units every 25 days since 2004. As of 10 September 2014 he still owns at least 382,446 units of Orasure Technologies stock.
You can see the complete history of Mr. Hobbs stock trades at the bottom of the page.
Eamonn P. Hobbs serves as Independent Director of the Company. Mr. Hobbs serves as President of Hobbs Medical Ventures, LLC, a consulting company he founded in the healthcare field. In March 2018, he co-founded and serves as Chairman of the Board and CEO of ImmunSYS, Inc. a company that is developing a new immunotherapy for late stage metastatic prostate cancer. From December 2016 to June 2017, Mr. Hobbs served as President and CEO of Digital Cognition Technologies, Inc., an early stage medical device company. From July 2014 to January 2016, Mr. Hobbs served as the President and Chief Executive Officer of Antares Pharma, Inc., a specialty pharmaceutical company focused on self-injection pharmaceutical products and technologies. He also served on the Antares board of directors from 2009 to 2016. From 2009 to 2013, Mr. Hobbs served as President and Chief Executive Officer, and from 2008 to 2013 was a member of the board of directors, of Delcath Systems, Inc., a specialty pharmaceutical and medical device public company specializing in cancer treatment. Prior to Delcath Systems, Inc., Mr. Hobbs served as President and Chief Executive Officer of AngioDynamics, Inc., a company he co-founded in 1988 as a division of E-Z-EM, Inc. which grew into a leading medical technology public company with a highly diverse product line. From 1988 to 2004, Mr. Hobbs also served as Executive Vice President of Business Development of E-Z-EM, Inc., a NASDAQ-traded company. Before joining AngioDynamics, Mr. Hobbs was Director of Marketing and Product Development at NAMIC; founder, President and Chief Executive Officer of Hobbs Medical, Inc.; and a Product Development Engineer at Cook Incorporated. Mr. Hobbs received a B.S. in Plastics Engineering with a Biomaterials emphasis at the University of Massachusetts (Lowell). Mr. Hobbs has served on the Board of Directors of the Medical Device Manufacturers Association since 2009.
As the Independent Director of Orasure Technologies, the total compensation of Eamonn Hobbs at Orasure Technologies is 183,305$. There are 9 executives at Orasure Technologies getting paid more, with Stephen Tang having the highest compensation of 2,114,820$.
Eamonn Hobbs is 61, he's been the Independent Director of Orasure Technologies since 2016. There are 1 older and 15 younger executives at Orasure Technologies. The oldest executive at Orasure Technologies Inc. is Ronny Lancaster, 68, who is the Independent Director.
Eamonn's mailing address filed with the SEC is 220 EAST FIRST STREET, , BETHLEHEM, PA, 18015.
Over the last 21 years, insiders at Orasure Technologies have traded over 21,897,384$ worth of Orasure Technologies stock and bought 196,200 units worth 1,037,188$ . The most active insiders traders include Douglas A Michels、Ronald H Spair、Michael J Gausling. On average, Orasure Technologies executives and independent directors trade stock every 43 days with the average trade being worth of 221,123$. The most recent stock trade was executed by Kathleen Gallagher Weber on 19 December 2023, trading 24,129 units of OSUR stock currently worth 194,238$.
based in bethlehem, pennsylvania, orasure technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. these products include tests for the detection of antibodies to the hiv virus, including the oraquick® in-home hiv test, oraquick advance® rapid hiv-1/2 antibody test and the orasure® hiv-1 oral specimen collection device, a test for antibodies to the hcv virus, the oraquick® hcv rapid antibody test, and oral fluid testing solutions for drugs of abuse testing, including intercept® oral fluid drug testing system and q.e.d.® saliva alcohol test. orasure also manufactures and sells several leading cryosurgical products. these include: histofreezer®, a product for the cryosurgical removal of common and plantar warts and several other benign skin lesions, sold to the professional or physician office market, as well as an over-the-counter product fo
Orasure Technologies executives and other stock owners filed with the SEC include: